Identification of Tau and SOD1 gene mutation in a small Chinese Han pedigree of adult amyotrophic lateral sclerosis

Neurocase ◽  
2013 ◽  
Vol 19 (5) ◽  
pp. 497-504 ◽  
Author(s):  
Renshi Xu ◽  
Bei Shao ◽  
Chengsi Wu ◽  
Yunzhu Yang ◽  
Hanmin Wang ◽  
...  
2003 ◽  
Vol 206 (1) ◽  
pp. 65-69 ◽  
Author(s):  
Nam-Hee Kim ◽  
Hyun-Jung Kim ◽  
Manho Kim ◽  
Kwang-Woo Lee

2013 ◽  
Vol 44 (6) ◽  
pp. 1171-1176 ◽  
Author(s):  
Yo-ichi Takei ◽  
Kenya Oguchi ◽  
Hiroshi Koshihara ◽  
Akiyo Hineno ◽  
Akinori Nakamura ◽  
...  

2007 ◽  
Vol 113 (5) ◽  
pp. 535-542 ◽  
Author(s):  
Chun-Feng Tan ◽  
Hiroto Eguchi ◽  
Asako Tagawa ◽  
Osamu Onodera ◽  
Takuya Iwasaki ◽  
...  

2013 ◽  
Vol 34 (6) ◽  
pp. 1709.e3-1709.e5 ◽  
Author(s):  
Rosanna Tortelli ◽  
Francesca Luisa Conforti ◽  
Rosa Cortese ◽  
Eustachio D'Errico ◽  
Eugenio Distaso ◽  
...  

Author(s):  
Katharine A. Nicholson ◽  
James D. Berry

The current state of amyotrophic lateral sclerosis (ALS) trial design is best understood within the context of ALS research over the past quarter century. Before the early 1990s, trials in ALS were typically small and clinical trial methodology was less rigorous than it is today. With the discovery of the SOD1 gene mutation in the early 1990s, a new era of excitement and innovation for ALS research began. Since then, the number of ALS trials has steadily increased and trial design and methodology has become increasingly sophisticated.


Sign in / Sign up

Export Citation Format

Share Document